Syncona Limited Achilles files registration statement (7762Q)
March 02 2021 - 2:00AM
UK Regulatory
TIDMSYNC
RNS Number : 7762Q
Syncona Limited
02 March 2021
Syncona Limited
02 March 2021
Achilles files registration statement for proposed initial public offering in the United States
Syncona Ltd, a leading healthcare company focused on founding,
building and funding a portfolio of global leaders in life science,
notes that its portfolio company, Achilles Therapeutics plc
("Achilles"), a clinical-stage biopharmaceutical company developing
precision T cell therapies to treat solid tumours, announced it has
filed a registration statement on Form F-1 (the "Registration
Statement") with the U.S. Securities and Exchange Commission (the
"SEC") relating to a proposed initial public offering ("IPO") in
the United States of its American Depositary Shares ("ADSs"), each
representing one ordinary share of Achilles. All ADSs to be sold in
the proposed IPO will be offered by Achilles. The number of ADSs to
be sold and the pricing terms for the proposed IPO have not yet
been determined.
J.P. Morgan, BofA Securities and Piper Sandler are expected to
act as joint book-running managers for the offering. Chardan,
Oppenheimer & Co, and Kempen & Co are expected to act as
co-managers.
The Registration Statement relating to the securities has been
filed with the SEC but has not yet become effective. These
securities may not be sold, nor may offers be accepted, prior to
the registration statement becoming effective. This announcement
shall not constitute an offer to sell or the solicitation of an
offer to buy, nor shall there be any sale of, these securities in
any state or jurisdiction in which such offer, solicitation, or
sale would be unlawful prior to registration or qualification of
these securities under the securities laws of any such state or
jurisdiction.
The securities referred to in this announcement are to be
offered only by means of a prospectus. When available, copies of
the preliminary prospectus relating to and describing the terms of
the proposed IPO can be obtained from the following sources:
-- J.P. Morgan Securities LLC, Attention Equity Syndicate Desk,
383 Madison Avenue, New York, New York 10179, or via email:
prospectuseq_fi@jpmchase.com ;
-- BofA Securities, Attention: Prospectus Department,
NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC
28255-0001, or via email: dg.prospectus_requests@bofa.com; or
-- Piper Sandler & Co., Attention: Prospectus Department,
800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone:
(800) 747-3924, or via email: prospectus@psc.com.
Achilles has applied to list its ADSs on The Nasdaq Global
Market under the symbol "ACHL."
[ENDS]
Forward-looking statements - this announcement contains certain
forward-looking statements with respect to the portfolio of
investments of Syncona Limited. These statements and forecasts
involve risk and uncertainty because they relate to events and
depend upon circumstances that may or may not occur in the future.
There are a number of factors that could cause actual results or
developments to differ materially from those expressed or implied
by these forward-looking statements. In particular, many companies
in the Syncona Limited portfolio are conducting scientific research
and clinical trials where the outcome is inherently uncertain and
there is significant risk of negative results or adverse events
arising. In addition, many companies in the Syncona Limited
portfolio have yet to commercialise a product and their ability to
do so may be affected by operational, commercial and other
risks.
Enquiries
Syncona Ltd
Annabel Clay
Tel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
About Syncona
Syncona's purpose is to invest to extend and enhance human life.
We do this by founding, building and funding a portfolio of global
leaders in life science, to deliver transformational treatments to
patients in areas of high unmet need.
Our strategy is to found, build and fund companies around
exceptional science to create a dynamic portfolio of 15-20 globally
leading healthcare businesses for the benefit of all our
stakeholders. We focus on developing treatments for patients by
working in close partnership with world-class academic founders and
management teams. Our strategic balance sheet underpins our
strategy enabling us to take a long-term view as we look to improve
the lives of patients with no or few treatment options, build
sustainable life science companies and deliver strong risk-adjusted
returns to shareholders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PFUSSDFUFEFSELD
(END) Dow Jones Newswires
March 02, 2021 02:00 ET (07:00 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2023 to Apr 2024